SoftOx Solutions AS (OSL:SOFTX)

Norway flag Norway · Delayed Price · Currency is NOK
0.101
+0.003 (2.54%)
At close: Apr 28, 2026
-2.88%
Market Cap 252.04M
Revenue (ttm) 15.58M
Net Income (ttm) -10.81M
Shares Out 2.50B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,727,580
Average Volume 96,158,000
Open 0.100
Previous Close 0.099
Day's Range 0.096 - 0.107
52-Week Range 0.049 - 0.175
Beta 0.99
RSI 48.94
Earnings Date May 27, 2026

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norwa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 2
Stock Exchange Oslo Børs
Ticker Symbol SOFTX
Full Company Profile

Financial Performance

In 2025, SoftOx Solutions AS's revenue was 15.58 million, an increase of 96.92% compared to the previous year's 7.91 million. Losses were -10.81 million, -74.82% less than in 2024.

Financial Statements

News

SoftOx Solutions AS Transcript: Investor Update

A stabilized hypochlorous acid inhalation solution is advancing to a Phase 2a proof-of-concept study in cystic fibrosis, targeting robust bacterial load reduction as a key milestone. Significant market opportunities exist in CF and NCFB, supported by a flexible equity facility and a focus on attracting pharma partners by 2027.

8 months ago - Transcripts

SoftOx Solutions AS Transcript: Investor Update

A new management team will lead a lean, project-focused organization, prioritizing a Phase II trial for ventilator-associated pneumonia with strong preclinical and Phase I data. Funding efforts target NOK 60-80 million, with industrial partnerships sought post-trial.

1 year ago - Transcripts